Description:

Bolasterone is an oral anabolic steroid structurally similar to methyltestosterone. The difference lies in the addition of a methyl group at the C-7 position, making its chemical name 7,17-dimethyltestosterone. The added C-7 methyl group makes this steroid's activity significantly different from methyltestosterone, and the two cannot be directly compared. For starters, Bolasterone is quite potent, with an anabolic effect measured in human subjects to be about twice that of Dianabol. In contrast, the potency of methyltestosterone is much lower than that of Dianabol. Despite being a testosterone derivative, Bolasterone exhibits more anabolic than androgenic properties. At therapeutic levels, it is less likely to cause androgenic/worsening side effects. Bolasterone does share strong similarities with methyltestosterone but retains estrogenic properties. These two drugs are best used during bulking phases or training periods.

History:

Bolasterone first appeared in 1959. About three years later, its anabolic and androgenic properties were closely evaluated. The drug was developed by Upjohn and marketed in the United States under the brand name Myagen during the 1960s. It was primarily used to treat advanced breast cancer in women and was also used for stimulating blood cells and general anabolic activity. Bolasterone was a short-lived drug, disappearing from the U.S. market shortly after its release. By the 1980s, Bolasterone had been forgotten by athletes for a long time. Although Bolasterone is no longer produced, it remains listed in the United States Pharmacopeia, suggesting that its reappearance in the U.S. might be possible through custom orders from private compounding pharmacies. However, the actual commercial reappearance of Bolasterone remains highly unlikely.